Direct oral anticoagulants and cancer-associated VTE: good for all, or just some?
Why the study?
Venous thromboembolism is associated with significant mortality and morbidity in cancer patients, making tailored anticoagulation essential to reduce recurrent VTE while minimizing bleeding.
Do direct oral anticoagulants reduce recurrent VTE and bleeding compared to low-molecular-weight heparin in patients with cancer-associated VTE?
Comparison
Direct oral anticoagulants vs low-molecular-weight heparin
Authors
Discussion
Loading...
Member takes
Implication
May support individualized DOAC consideration in cancer VTE; leaves open optimal selection criteria for future trials.
Structured PICO
Do direct oral anticoagulants reduce recurrent VTE and bleeding compared to low-molecular-weight heparin in patients with cancer-associated VTE?
P
Population
Patients with cancer and acute cancer-associated venous thromboembolism (VTE)
I
Intervention
Direct oral anticoagulants
C
Comparator
Low-molecular-weight heparin
O
Outcome
Recurrent VTE and bleeding risk
Direct oral anticoagulants are a viable alternative to low-molecular-weight heparin for cancer-associated VTE, but require individualized decision-making based on patient characteristics and interactions.
Cite This Study
Carrier et al. (2020) studied this question.